Disclosure Of Entity's Operating Segments [Text Block]

ABIONYX Pharma - Filing #2813091

Concept As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
Disclosure of entity's operating segments [text block]
Soldes et explications
Disclosure of operating segments [text block]
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Revenue
5 252 EUR
675,000 EUR
Interest expense
- EUR
- EUR
Profit (loss)
4 206 EUR
4 206 EUR
5 822 EUR
5 822 EUR
Assets
15 823 EUR
21 832 EUR
Cash flows from (used in) operating activities
3 359 EUR
6 692 EUR
Cash flows from (used in) investing activities
175,000 EUR
1 338 EUR
Cash flows from (used in) financing activities
194,000 EUR
3 972 EUR
Disclosure of products and services [text block]
Disclosure of products and services [abstract]
Disclosure of products and services [line items]
Disclosure of geographical areas [text block]
Disclosure of geographical areas [abstract]
Disclosure of geographical areas [line items]
Disclosure of major customers [text block]
Disclosure of major customers [abstract]
Disclosure of major customers [line items]

Talk to a Data Expert

Have a question? We'll get back to you promptly.